Table 3.
Coenzyme Q10 Concentrations in Several Tissues from Patients with Lewy Body Dementia (LBD), Progressive Supranuclear Palsy, and Cortical Basal Degeneration Compared with Healthy Controls (HC).
| Lewy Body Dementia (LBD) | |||||||
|---|---|---|---|---|---|---|---|
| Tissue | Author, Year [Ref] | Parameter | LBD N | LBD Mean ± SD | HC N | HC Mean ± SD | Difference in Means (95% C.I.), p |
| Serum/plasma | Molina et al., 2002 [26] | Total CoQ10 (nmol/L) | 18 | 960.6 ± 359.1 | 20 | 1205.2 ± 362.2 | 244.60 (6.90 to 482.30); 0.044 |
| Gironi et al. 2011 [27] | Total CoQ10 (nmol/L) | 7 | 645.17 ± 290 | 66 | 622.12 ± 227.14 | −23.05 (−207.81 to 161.71); 0.804 | |
| TOTAL SERIES | Total CoQ10 (nmol/L) | 25 | 872.28 ± 365.05 | 86 | 757.72 ± 360.79 | Random-effects model: p = 0.409 | |
| Molina et al., 2002 [7] | Total CoQ10/cholesterol | 18 | 4.67 ± 1.75 | 20 | 5.05 ± 1.52 | 0.38 (−0.70 to 1.46); 0.478 | |
| Brain | |||||||
| Cerebellum cortex | Schottlaender et al., 2016 [21] | Total CoQ10 (pmol/mg) | 20 | 169.30 ± 49.71 | 37 | 241.87 ± 57.70 | 72.57 (41.94 to 103.20); <0.001 |
| Cerebral cortex frontal | Schottlaender et al., 2016 [21] | Total CoQ10 (pmol/mg) | 20 | 260.44 ± 70.22 | 37 | 259.39 ± 107.09 | −1.05 (−54.43 to 52.33); 0.969 |
| Progressive Supranuclear Palsy (PSP) | |||||||
| Tissue | Author, Year [Ref] | Parameter | PSP N | PSP Mean ± SD | HC N | HC Mean ± SD | Difference in Means (95% C.I.), p |
| CSF | Compta et al., 2018 [19] | Total CoQ10 (nmol/L) | 10 | 47.67 ± 4.05 | 15 | 36.02 ± 7.10 | −11.65 (−16.79 to −6.51); 0.0001 |
| Cortical Basal Degeneration (CBD) | |||||||
| TISSUE | Author, Year [Ref] | Parameter | CBD N | CBD Mean ± SD | HC N | HC Mean ± SD | Difference in Means (95% C.I.), p |
| Cerebellum cortex | Schottlaender et al., 2016 [21] | Total CoQ10 (pmol/mg) | 15 | 271.18 ± 76.21 | 37 | 241.87 ± 57.70 | −29.31 (−68.31 to 9.69); 0.137 |